文献速递头颈外科

晚期头颈癌的新型免疫调节药物

Novel immune-modulating drugs for advanced head and neck cancer.
PubMed 文献 · Head Neck · 2019-01-01

本文综述1992至2019年发表的关于头颈癌免疫调节药物的免疫学/生物学机制及早期临床试验结果的文献。描述了11种用于晚期头颈癌的免疫调节药物,包括小分子、抗体和治疗性疫苗。几乎所有11种药物作为单药或联合治疗均观察到治疗反应,显示出提高疗效并维持可耐受安全性的潜力。

要点

  • 综述涵盖11种免疫调节药物,包括小分子、抗体和治疗性疫苗。
  • 几乎所有药物作为单药或联合治疗均观察到治疗反应。
  • 新型免疫调节药物有望提高头颈癌疗效并维持可耐受的安全性。

核心结论

  • 新型免疫调节药物在晚期头颈癌中显示出提高治疗疗效并维持可耐受安全性的潜力。

研究设计与样本

  • 综述1992至2019年发表的关于头颈癌免疫调节药物的免疫学/生物学机制及早期临床试验结果的文献。

主要发现

  • 描述了11种用于晚期头颈癌的免疫调节药物,包括小分子、抗体和治疗性疫苗。
  • 几乎所有11种药物作为单药或联合治疗均观察到治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recently, two anti-PD-1 immune checkpoint inhibitors, pembrolizumab and nivolumab, have been approved by the US Food and Drug Administration for patients who fail on platinum-based chemotherapy. However, overall response and progression-free survival are still limited, and multiple novel agents are under development to fulfill this unmet clinical need. METHODS: Publications between 1992 and 2019 regarding the immunological/biological mechanisms and early phase clinical trial outcomes of immunomodulatory agents for head and neck cancer were described in this review article. RESULTS: Eleven immunomodulatory agents for advanced head and neck, including small molecules, antibodies, and therapeutic vaccines were described. Treatment responses were noted in nearly all 11 agents, as monotherapy or combination therapy. CONCLUSIONS: Potentials of the novel immunomodulatory agents to improve treatment efficacy of head and neck cancer and to maintain tolerable safety profile have been disclosed.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Chen TH, Chang PM, Yang MH, et al. Novel immune-modulating drugs for advanced head and neck cancer. Head Neck. 2019. PMID: 31573750. doi:10.1002/hed.25929

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。